Novel Drug Targets and Strategies for Asthma and Chronic Obstructive Pulmonary Disease

Published by: Decision Resources

Published: Sep. 1, 2011

Table of Contents

Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction to Asthma and COPD

Overview of Asthma

Novel Targets and Drug Development for Asthma

Anticytokine Agents

Chemokine Receptor Antagonists

Kinase Inhibitors

Potassium-Channel Modulators

OX40 Ligand Antagonists

Overview of COPD

Novel Targets and Drug Development for COPD

Protease Inhibitors

Retinoic Acid Receptor Agonists

Anticytokine Agents

Chemokine Receptor Antagonists

Kinase Inhibitors

Potassium-Channel Modulators

Broad-Spectrum Anti-Inflammatories

Innovative Company Activity

Aerovance

Amira Pharmaceuticals

BioMarck Therapeutics

Oxagen

Revotar

Outlook

Asthma

COPD

Bibliography

About the Author

Look for relevant insight within these Spectrum series and related Spectrum reports:

Abstract

• Multiple treatment options are available for patients with asthma and COPD. How large are the current asthma and COPD markets? How will the size of these markets change in the future? What types of opportunities are available?
• The majority of asthma patients benefit adequately from current therapies, but patients with severe refractory asthma need new options. What therapies are available for patients with severe refractory asthma? Which novel targets are under investigation for asthma drugs? Which compounds targeting these mechanisms are the most promising? Which innovators are developing asthma drugs against novel targets?
• Current therapies for COPD are used primarily to address patients' symptoms; no disease-modifying drugs are available. What strategies are developers using to identify disease-modifying drugs and agents that target COPD-specific inflammation? Which novel targets are under investigation for COPD drugs? Which compounds targeting these mechanisms are most promising? Which innovators are developing COPD drugs against novel targets?
• Asthma and COPD are heterogeneous diseases. What impact will heterogeneity have on drug development for asthma and COPD? How will heterogeneity impact business models in these fields?
• The need for novel drugs against new targets and mechanisms of action provides opportunities for biotech and specialty pharma. Which companies have novel platforms for innovative respiratory drug development? What drugs are innovator companies developing? What corporate partnerships have these companies formed? What companies have been involved in M&As?

• Overview of asthma: Overview, market size and forecast, unmet needs, opportunities.
• Novel targets and strategies for asthma: Mechanisms of action, inflammation, opportunities, novel targets.
• Overview of COPD: Overview, market size and forecast, unmet needs, opportunities.
• Novel targets and strategies for COPD: Mechanisms of action, inflammation, opportunities, novel targets.
• Innovation company activity: Innovative biotech and specialty pharma companies, technology focus, partnerships, M&As.
• Outlook for asthma and COPD: Changing business models, emerging therapies and strategies, genetic factors, heightened regulatory scrutiny, genetic influences, government-sponsored initiatives.
• Primary data: Survey results of 51 pulmonologists and 54 primary-care physicians conducted by Decision Resources in July 2011.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.